E-resources
-
Kaptein, Suzanne J. F.; Jacobs, Sofie; Langendries, Lana; Seldeslachts, Laura; ter Horst, Sebastiaan; Liesenborghs, Laurens; Hens, Bart; Vergote, Valentijn; Heylen, Elisabeth; Barthelemy, Karine; Maas, Elke; De Keyzer, Carolien; Bervoets, Lindsey; Rymenants, Jasper; Van Buyten, Tina; Zhang, Xin; Abdelnabi, Rana; Pang, Juanita; Williams, Rachel; Thibaut, Hendrik Jan; Dallmeier, Kai; Boudewijns, Robbert; Wouters, Jens; Augustijns, Patrick; Verougstraete, Nick; Cawthorne, Christopher; Breuer, Judith; Solas, Caroline; Weynand, Birgit; Annaert, Pieter; Spriet, Isabel; Velde, Greetje Vande; Neyts, Johan; Rocha-Pereira, Joana; Delang, Leen
Proceedings of the National Academy of Sciences - PNAS, 10/2020, Volume: 117, Issue: 43Journal Article
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) rapidly spread around the globe after its emergence in Wuhan in December 2019. With no specific therapeutic and prophylactic options available, the virus has infected millions of people of which more than half a million succumbed to the viral disease, COVID-19. The urgent need for an effective treatment together with a lack of small animal infection models has led to clinical trials using repurposed drugs without preclinical evidence of their in vivo efficacy. We established an infection model in Syrian hamsters to evaluate the efficacy of small molecules on both infection and transmission. Treatment of SARS-CoV-2–infected hamsters with a low dose of favipiravir or hydroxychloroquine with(out) azithromycin resulted in, respectively, a mild or no reduction in virus levels. However, high doses of favipiravir significantly reduced infectious virus titers in the lungs and markedly improved lung histopathology. Moreover, a high dose of favipiravir decreased virus transmission by direct contact, whereas hydroxychloroquine failed as prophylaxis. Pharmacokinetic modeling of hydroxychloroquine suggested that the total lung exposure to the drug did not cause the failure. Our data on hydroxychloroquine (together with previous reports in macaques and ferrets) thus provide no scientific basis for the use of this drug in COVID-19 patients. In contrast, the results with favipiravir demonstrate that an antiviral drug at nontoxic doses exhibits a marked protective effect against SARS-CoV-2 in a small animal model. Clinical studies are required to assess whether a similar antiviral effect is achievable in humans without toxic effects.
Author
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Shelf entry
Permalink
- URL:
Impact factor
Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.
Year | Impact factor | Edition | Category | Classification | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Select the library membership card:
If the library membership card is not in the list,
add a new one.
DRS, in which the journal is indexed
Database name | Field | Year |
---|
Links to authors' personal bibliographies | Links to information on researchers in the SICRIS system |
---|
Source: Personal bibliographies
and: SICRIS
The material is available in full text. If you wish to order the material anyway, click the Continue button.